Dova Pharmaceuticals to Present at Upcoming Investor Conferences
04 September 2019 - 6:30AM
Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr.
David Zaccardelli, President & Chief Executive Officer, will
present company overviews at two upcoming investor conferences:
- H.C. Wainwright 21st Annual Global Investment Conference on
Monday, September 9, 2019 at 12:30 p.m. ET in New York, NY.
- Ladenburg Thalmann 2019 Healthcare Conference on Tuesday,
September 24, 2019 at 2:30 p.m. ET in New York, NY.
A live audio webcast of each event will be
available via the "Investor Relations" page of the Dova website,
www.dova.com. Please log on through Dova's website approximately 10
minutes before the scheduled start times. A replay of the webcast
will be archived on Dova's website for 90 days following the
call.
About Dova Pharmaceuticals,
Inc.
Dova is a pharmaceutical company focused on
acquiring, developing, and commercializing drug candidates for
diseases where there is a high unmet need, with an initial focus on
addressing thrombocytopenia. Dova’s proprietary pipeline includes
one commercial product, DOPTELET®, for the treatment of
thrombocytopenia in adult patients with chronic liver disease
scheduled to undergo a procedure and the treatment of
thrombocytopenia in adults with chronic immune thrombocytopenia who
have had an insufficient response to a previous treatment. For more
information, visit www.Dova.com.
Contacts
Mark W. HahnChief Financial Officer(919)
338-7936mhahn@dova.com
Westwicke John Woolford(443)
213-0506john.woolford@westwicke.com
Dova Pharmaceuticals (NASDAQ:DOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dova Pharmaceuticals (NASDAQ:DOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Dova Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles